Caption Management’s Travere Therapeutics TVTX Stock Holding History

Caption Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$743K	Buy	+25,000	New	+$747K	﹤0.01%	1104
2025 Q4	–	Sell	-60,193	Closed	-$1.96M	–	2074
2025 Q3	$1.44M	Buy	+60,193	New	+$1.13M	0.01%	974
2024 Q3	–	Sell	-28,011	Closed	-$292K	–	1592
2024 Q2	$230K	Buy	28,011 +11,204	+67%	+$75.5K	﹤0.01%	937
2024 Q1	$130K	Buy	+16,807	New	+$142K	﹤0.01%	1036
2022 Q4	–	Sell	-10,200	Closed	-$251K	–	1723
2022 Q3	$251K	Buy	+10,200	New	+$264K	﹤0.01%	1212

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caption Management's TVTX Position: Q1 2026 in Review

Caption Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 25,000 shares worth $743K. The stake represents ﹤0.01% of the portfolio and ranks #1104 among its holdings. This is a return to the name: Caption Management previously reported a position in TVTX as recently as Q3 2025.

Caption Management first reported a position in TVTX in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.44M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Caption Management held 25,000 shares of Travere Therapeutics worth $743K as of Q1 2026.
Travere Therapeutics was a new Caption Management position in Q1 2026.
Travere Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1104 holding.
Caption Management first reported a position in Travere Therapeutics in Q3 2022 and has held it in 5 quarters since.
Caption Management's Travere Therapeutics position peaked at $1.44M in Q3 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.